therapy
2010-2011 Psychiatric Pharmacy Review Course - ACPE Credit Only
The Psychiatric Pharmacy Review Course (Review Course) is an excellent course of study and resource for those seeking a review of psychopharmacology and current standards of care. Read more about this session.
Omega-3 Fatty Acid Augmentation of Citalopram Treatment for Patients With Major Depressive Disorder
Objective: The objective of this study was to explore the efficacy of combination therapy with citalopram plus omega-3 fatty acids versus citalopram plus placebo (olive oil) in the initial treatment of individuals with major depressive disorder (MDD).
Breast-cancer adjuvant therapy with zoledronic acid.
van der Vliet HJ, Verheul HM | |
[Correspondence] Exon-skipping therapy for Duchenne muscular dystrophy – Authors' reply
Satyakam Bhagavati questions the choice of biochemical outcome measures in our systemic phase 2 exon-skipping study of Duchenne muscular dystrophy. He suggests two RNA-based assays (quantitative RNAse protection and northern-blot analysis), which are theoretically feasible but difficult to do and limited in their scope. To assess exon skipping at the RNA level, we used the standard methods that are regularly used on both animal and human tissue, and in all the published clinical trials to date.
[Correspondence] Exon-skipping therapy for Duchenne muscular dystrophy
Sebahattin Cirak and colleagues (Aug 13, p 595) report impressive results with systemic exon-skipping therapy for patients with Duchenne muscular dystrophy. However, reliance on immunohistochemistry and western blots alone could be very misleading. Of other factors, non-specific, false-positive signals from muscle membrane and inaccurate immunoblot quantitation because of biopsy sample variations are difficult to eliminate.
Lung Transplantation Across Donor-Specific Anti-Human Leukocyte Antigen Antibodies: Utility of Bortezomib Therapy in Early Graft Dysfunction
OBJECTIVE: To report the usefulness of bortezomib therapy in a sensitized lung transplant recipient experiencing antibody-mediated rejection.
Daclizumab Use in Patients With Pediatric Multiple Sclerosis [Original Contribution]
Background Daclizumab, a humanized monoclonal antibody specific for the interleukin 2 receptor α chain, reduces clinical and magnetic resonance imaging disease activity in patients with adult-onset multiple sclerosis (MS) as monotherapy or add-on therapy with interferon.
Objective To report the use of daclizumab in pediatric-onset MS.
Design Case series.
Setting Two comprehensive pediatric MS centers.